


CLAIMS


1. Use of a compound of the following formula (I)



(I)

or a pharmaceutically acceptable salt, or solvate thereof, for the preparation of a medicament for the treatment or prevention of levodopa-induced dyskinesia.

2. The use of claim 1, wherein said compound has the (E)-configuration at the oxime group comprised in formula (I).
3. The use of claim 1 or 2, wherein said compound is in the form of a hydrochloride salt.
4. The use of any one of claims 1 to 3, wherein said medicament is for oral administration.
5. Use of a compound of the following formula (I)




(I)

or a pharmaceutically acceptable salt, or solvate thereof, for the preparation

of a medicament for the treatment or prevention of Parkinson's disease, wherein said medicament is to be administered in combination with levodopa or a pharmaceutically acceptable salt, or solvate thereof.

6. Use of levodopa or a pharmaceutically acceptable salt, or solvate thereof for the preparation of a medicament for the treatment or prevention of Parkinson's disease, wherein said medicament is to be administered in combination with a compound of the following formula (I)




(I)

or a pharmaceutically acceptable salt, or solvate thereof.

7. The use of claim 5 or 6, wherein the compound of formula (I) has the (E)-configuration at the oxime group comprised in formula (I).
8. The use of any one of claims 5 to 7, wherein the compound of formula (I) is in the form of a hydrochloride salt.
9. The use of any one of claims 5 to 8, wherein said compound of formula (I) or the pharmaceutically acceptable salt, or solvate thereof and said levodopa or the pharmaceutically acceptable salt, or solvate thereof are to be administered simultaneously.
10. The use of claim 9, wherein said compound of formula (I) or the pharmaceutically acceptable salt, or solvate thereof and said levodopa or the pharmaceutically acceptable salt, or solvate thereof are provided in a single medicament.
11. The use of claim 9, wherein said compound of formula (I) or the pharmaceutically acceptable salt, or solvate thereof and said levodopa or the pharmaceutically acceptable salt, or solvate thereof are provided in separate medicaments.

12. The use of any one of claims 5 to 8, wherein said compound of formula (I) or the pharmaceutically acceptable salt, or solvate thereof and said levodopa or the pharmaceutically acceptable salt, or solvate thereof are to be administered sequentially.
13. The use of any one of claims 5 to 12, wherein the medicament(s) comprising said compound of formula (I) or the pharmaceutically acceptable salt, or solvate thereof and said levodopa or the pharmaceutically acceptable salt, or solvate thereof is/are for oral administration.
14. Use of a first compound and a second compound for the preparation of a medicament for the treatment or prevention of Parkinson's disease,

wherein said first compound is a compound of the following formula (I)



(I)

or a pharmaceutically acceptable salt, or solvate thereof,

and wherein said second compound is levodopa or a pharmaceutically acceptable salt, or solvate thereof.

15. The use of claim 14, wherein the compound of formula (I) has the (E)-configuration at the oxime group comprised in formula (I).
16. The use of claim 14 or 15, wherein the compound of formula (I) is in the form of a hydrochloride salt.
17. The use of any one of claims 14 to 16, wherein said medicament is for oral administration.